NRG Oncology

What NRG Oncology does

NRG Oncology Foundation, Inc. is a Philadelphia-based nonprofit clinical research cooperative group formed in 2014 from the merger of three legacy National Cancer Institute (NCI) cooperative groups — the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG) — bringing together more than 150 years of cumulative experience in practice-defining oncology trials. It operates as a Lead Protocol Organization within the NCI's National Clinical Trials Network (NCTN), designing and conducting multi-institutional Phase I, II, and III clinical trials and translational biological studies across brain, breast, gastrointestinal, genitourinary, gynecologic, head and neck, and lung cancers, with a particular focus on sex-specific malignancies and localized or locally advanced disease.

The organization's core technical infrastructure comprises four interconnected units: the Statistics and Data Management Center (SDMC), headquartered at the University of Chicago with additional offices in Philadelphia and Buffalo; the Biospecimen Bank, with sites in Columbus, Pittsburgh, and San Francisco holding over 3.5 million specimens from more than 363,000 patients; the Center for Innovation in Radiation Oncology (CIRO), which produces contouring atlases and radiation therapy research tools; and the NRG NCORP Research Base, which extends trials into community oncology settings. NRG operates with a small core staff (51-100 employees) supported by more than 1,000 member sites across five continents.

NRG Oncology is funded primarily through NCI grants, including a $66 million renewal award to the SDMC at the University of Chicago in 2026; it does not generate commercial product revenue. Its customers in the participation sense are its 1,000+ member institutions and the cancer patients enrolled in its trials, while its de facto economic counterparty is the U.S. federal government via the NCI. The organization disseminates findings through peer-reviewed publications, presentations at major oncology meetings (ASCO, ASTRO, SABCS, ASCO GI), a semiannual meeting cadence, weekly broadcasts, newsletters, and a 2025 ACRO Media Award-winning podcast.

Name

NRG Oncology

Legal name

NRG Oncology Foundation, Inc.

Website

https://nrgoncology.org

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

NRG Oncology Foundation is a Philadelphia-based nonprofit clinical research cooperative group that designs and conducts multi-institutional NCI-sponsored oncology trials across a 1,000+ member site network, integrating biostatistics, biospecimen banking, and radiation oncology research.

Ownership category

akta.pro rank

Product category

Oncology Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Oncology clinical trials
• Clinical research organization
• Cancer research consortium
• Radiation oncology research
• Clinical data management

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels3 records

Marketing channels7 records

Core offering

NRG Oncology designs, conducts, and analyzes multi-institutional Phase I, II, and III oncology clinical trials primarily sponsored by the National Cancer Institute. It supports this research through specialized centers for statistics and data management, biospecimen banking, and radiation oncology innovation, serving member institutions across more than 1,000 sites worldwide.

Product overview

NRG Oncology is a clinical research cooperative group conducting multi-institutional clinical trials sponsored by the National Cancer Institute. The organization operates as a unified platform combining its core clinical trials infrastructure with specialized research centers and member services. The main offerings include: NRG Oncology Clinical Trials (phase I-III trials across brain, lung, breast, prostate, gynecologic, GI, head and neck cancers); the Statistics and Data Management Center (SDMC) providing biostatistics and data management expertise; the NRG NCORP Research Base for community oncology research; the Center for Innovation in Radiation Oncology (CIRO) with contouring tools and atlases; and the Biospecimen Bank with over 3.5 million specimens. Supporting products include member portals (NRG Apps), patient education materials, the NRG Oncology Podcast, weekly broadcasts, newsletters, and education/training programs via CLASS and VisionTree platforms.

Differentiator

Problem solved

Functional benefit

Brands

• NRG NCORP: National Cancer Institute Community Oncology Research Program Research Base that conducts clinical trials of cancer prevention, control, screening, and post treatment surveillance, as well as cancer care delivery research.
• CIRO

Products and services

• NRG Oncology Clinical Trials
• Statistics and Data Management Center (SDMC)
• NRG NCORP Research Base
• Center for Innovation in Radiation Oncology (CIRO)
• NRG Oncology Biospecimen Bank

Quantifiable outcome

• Prostate cancer patients could halve their radiation treatments without loss of effectiveness
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core.

• National Cancer Institute's ComboMATCH PlatformcoreStrategic or Co-development Partner · 10 March 2026NRG Oncology participates in the NCI's ComboMATCH platform trials, which evaluate combination therapies in adults and children with cancer to identify treatment regimens that outperform standard care. Foundation Medicine contributes biomarker testing to these trials.
• NRG Oncology/AlliancecoreStrategic or Co-development Partner · 18 February 2026NRG Oncology/Alliance collaborative clinical trial investigating immunotherapy combinations for limited-stage small cell lung cancer. A phase 3 trial enrolled 544 patients to evaluate atezolizumab with chemoradiation therapy.
• ECOG-ACRIN Cancer Research GroupcoreStrategic or Co-development Partner · 15 January 2025ECOG-ACRIN is leading the Tomosynthesis Mammographic Imaging Screening Trial (TMIST), a large-scale breast cancer screening trial funded by NCI. NRG collaborates on this trial which achieved enrollment of 108,508 women at 133 sites across 10 countries, creating the world's largest curated dataset of breast cancer screening images and clinical data.
• University of ChicagocoreStrategic or Co-development PartnerThe Statistics and Data Management Center (SDMC) is headquartered at the University of Chicago, providing biostatistics expertise for design, conduct, and analysis of NRG clinical trials. James Dignam, PhD serves as Group Statistician and Executive Director of SDMC.
• Roswell Park Comprehensive Cancer CentercoreStrategic or Co-development PartnerAustin Miller, PhD, Associate Head of the Statistics Division of NRG SDMC and Lead Statistician of Rare Tumor and Ovarian Tumor Subcommittees, is based at Roswell Park Comprehensive Cancer Center. The Buffalo SDMC office is led from this location.
• Nationwide Children's Hospital (Columbus)coreStrategic or Co-development PartnerNRG Biospecimen Bank - Columbus is located at the Abigail Wexner Research Institute at Nationwide Children's Hospital. The facility relocated in October 2024 to a new 55,000 square foot building designed specifically for biobanking and laboratory operations.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Alliance for Clinical Trials in Oncology: An NCTN Lead Protocol Organization conducting multi-institutional oncology trials, formed through merger of CALGB, ACOSOG, and NCCTG. Co-leads the NRG-LU005 limited-stage SCLC trial with NRG and competes head-to-head for NCI funding and protocol authorship.
• ECOG-ACRIN Cancer Research Group: Another NCI-funded NCTN Lead Protocol Organization that conducts multi-institutional Phase 2/3 cancer clinical trials. NRG and ECOG-ACRIN are direct competitors for NCI grant dollars and sponsor trial assignments, and have a documented collaboration on TMIST.
• SWOG Cancer Research Network: An NCTN Lead Protocol Organization that conducts practice-changing cancer clinical trials across multiple disease sites. SWOG competes with NRG for NCI funding, protocol leadership in overlapping disease areas (breast, lung, GI), and member-site participation.
• Children's Oncology Group: The world's largest pediatric cancer research organization and an NCTN Lead Protocol Organization. While focused on pediatric oncology rather than adult, COG shares the cooperative-group model, NCI funding mechanics, and integrated SDMC infrastructure with NRG.

Others

• National Cancer Institute (NCI): Primary funder and programmatic parent of NRG through the National Clinical Trials Network structure. NCI provides grant funding and sets the competitive framework within which NRG operates alongside peer cooperative groups.
• Foundation Medicine: A molecular diagnostics company contributing biomarker testing for the NCI's ComboMATCH platform trials in which NRG participates. Functionally a translational science partner for NRG-led precision oncology trials.
• Imaging and Radiation Oncology Core (IROC): NCI-funded core providing credentialing for radiation therapy and diagnostic imaging across NCTN trials including those led by NRG. Operationally interdependent through the CIRO workflow.
• Clinical Trials Support Unit (CTSU): An NCI service that supports roster management, learning management (CLASS), and member services for NCTN cooperative groups including NRG. Provides shared infrastructure that NRG's members rely on.
• Medidata Solutions: Provider of the Rave Electronic Data Capture platform used by NRG's SDMC for clinical trial data management. A core technology vendor enabling NRG's trial operations.

Broad incumbents

• IQVIA: The world's largest commercial contract research organization, offering oncology clinical trial services to pharma sponsors globally. Represents the for-profit alternative model that increasingly competes with cooperative groups like NRG for industry-sponsored trials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@NRGOnc/podcasts
• Xx.com/nrgonc
• Facebookfacebook.com/nrgoncology
• LinkedInlinkedin.com/company/nrg-oncology-foundation-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NRG Oncology